ArticleCureus2025
Atypical Presentation of Late-Onset Toxic Anterior Segment Syndrome Following Cataract Surgery: Challenges in Diagnosis and Management.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxic anterior segment syndrome (TASS) is a rare, non-infectious inflammatory response following anterior segment surgery that can be challenging to distinguish from infectious endophthalmitis, which requires different treatments. This case report describes a 72-year-old male with controlled hypertension, diabetes, and hyperlipidemia who developed an atypical presentation of TASS following uncomplicated cataract surgery. On postoperative day 7, the patient exhibited significant visual decline and anterior segment inflammation, raising concern for endophthalmitis. Diagnostic challenges included the absence of pain, delayed symptom onset, and vitritis. Treatment with intravitreal corticosteroids and antibiotics led to gradual visual recovery, with final visual acuity of 20/20 by day 30. No specific causative agent for TASS was identified, but the case highlights the importance of early recognition and management, as well as the potential contribution of surgical equipment issues and systemic risk factors in TASS development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.